Skip to main content
PLOS One logoLink to PLOS One
. 2026 May 4;21(5):e0347599. doi: 10.1371/journal.pone.0347599

Screening macrophage polarization genes in spinal cord injury as therapeutic targets

Xiaowei Zha 1, Shen Cao 2,*
Editor: Sawar Khan3
PMCID: PMC13138653  PMID: 42081466

Abstract

Macrophage polarization correlates strongly with the progression and prognosis of spinal cord injury (SCI), yet the therapeutic potential of macrophage polarization-related genes (MPRGs) in SCI remains unexplored. This study identified hub genes associated with MPRGs for SCI diagnosis, prognosis, and therapy. Differentially expressed genes (DEGs) between SCI and control groups were intersected with MPRGs to identify six differentially expressed MPRGs (DE-MPRGs). Machine learning algorithms, including LASSO, RF, and XGBoost, selected three hub genes (Soat1, Comt, and Myo1f) with elevated expression in SCI samples. Functional enrichment analysis indicated involvement in immune-related pathways. Immune infiltration analysis revealed differences in 11 immune gene sets between SCI and controls, all positively correlated with the hub genes. In silico drug prediction identified 37 small molecules, including dexamethasone and atorvastatin, as potential modulators of macrophage polarization in SCI. Single-cell RNA sequencing showed significantly higher expression of all hub genes in M2 than in M1 macrophages. RT-qPCR validation confirmed upregulation of the hub genes in SCI models. These results highlight Soat1, Comt, and Myo1f as novel hub genes in SCI, offering insights into macrophage polarization mechanisms and potential therapeutic targets.

1. Introduction

Spinal cord injury (SCI) emerges as a critical neurological disorder from diverse traumatic episodes, inducing either partial or total disruption of neural operations [1]. Chief origins of SCI involve injury-provoking incidents, including falls, sports-induced harms, vehicle crashes, and slips, alongside non-injury-based contributors such as tumors and intervertebral disc disorders [2–4]. Projections worldwide reveal that exceeding two million persons endure the impacts of SCI [5–7]. In addition to the corporeal and emotional agony induced by SCI, the consequent complications exert a considerable economic and societal strain upon households and populations [5]. Although therapeutic modalities for SCI have progressed, exemplified by stem cell engraftment, viable approaches to neural regeneration continue to be scarce. Investigations in modern medicine strive to innovate interventions for spinal cord restoration, demanding a thorough comprehension of the molecular and neural pathways implicated in SCI development.

Following SCI, macrophages, key components of the inflammatory response, play a pivotal role in driving inflammatory processes [8–10]. After SCI, macrophage phenotypes undergo dynamic changes that may influence inflammatory progression, glial and fibrous scar formation, and spinal cord regeneration [11]. Macrophages have traditionally been categorized into two phenotypes: M1 and M2 [12]. M1 macrophages (classically activated macrophages) are the predominant phenotype at the injury site and secrete high levels of pro-inflammatory cytokines in response to stimulation from the injured microenvironment. These pro-inflammatory cytokines induce neurotoxicity, triggering the death of neural cells and impeding spinal cord regeneration [13]. In contrast, M2 macrophages (alternatively activated macrophages) attenuate inflammatory escalation and exert a neuroprotective effect by releasing anti-inflammatory factors and neurotrophic molecules, stimulating angiogenesis, and promoting neuronal and tissue regeneration [14]. Numerous studies have shown that promoting macrophage polarization from the M1 to the M2 phenotype enhances neuronal repair and motor function recovery while attenuating secondary injury in SCI [15]. Given the substantial influence of macrophage polarization on disease progression and prognosis, increasing attention has been directed toward macrophage polarization-related genes (MPRGs) [10]. MPRGs also participate in multiple biological processes, including immune regulation, metabolic homeostasis, autophagy, apoptosis, pathogen clearance, and neurological modulation [16–18]. Owing to their diverse roles in the immune system, regulating the upstream and downstream pathways of MPRGs is essential for maintaining immune homeostasis, modulating inflammatory responses, facilitating tissue repair, and supporting other physiological functions. Therefore, MPRGs may serve as potential therapeutic targets for SCI.

Accordingly, this study aims to identify hub genes among MPRGs with potential diagnostic and therapeutic value in SCI, thereby providing a theoretical basis for elucidating SCI pathogenesis and informing clinical interventions.

2. Materials and methods

2.1. Data source and preprocessing

Data sets associated with SCI, namely GSE213240, GSE183591, GSE45006, and GSE45550, have been obtained from the Gene Expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo/ [Accessed: March 15, 2023]). In particular, the GSE45550 collection, originating from Rattus norvegicus soleus muscle tissue, incorporates 18 specimens from SCI cases (at 3, 8, and 14 days following injury) along with 6 control specimens [19]. For GSE45006, isolation occurred from Rattus norvegicus spinal cord tissue, yielding 20 SCI specimens and 4 sham-operated controls across time points of 1 day, 3 days, 1 week, 2 weeks, and 8 weeks after injury. Similarly, GSE183591, drawn from Sprague Dawley (SD) rat spinal cord, features 16 SCI specimens and 4 sham-operated controls evaluated at 1 week, 2 weeks, 4 weeks, and 8 weeks post-injury [20]. The GSE213240 single-cell RNA sequencing (scRNA-seq) dataset (platform: GPL25947) consists of 8 spinal cord tissue samples from SCI patients, sequenced via high-throughput technology. Expression matrices, sample clinical information, and annotation files for the corresponding microarray platforms were obtained using the GEOquery package. Probe ID-to-gene name mappings were extracted from the annotation files, and probe IDs in the expression matrices were converted to gene names by merging the data. Gene name cleaning was then performed by splitting and removing redundant entries separated by spaces, followed by deduplication to retain unique expression records for each gene. Sample IDs and phenotypic data were extracted from the clinical information to construct group files, and the processed expression matrices and group information were saved as standardized files. To minimize biases due to small sample sizes, the “sva” R package was used to integrate the GSE45550 and GSE45006 datasets, which were subsequently designated as the training set. Batch effects were corrected using the ComBat algorithm (based on an empirical Bayesian framework) prior to merging, and post-merge principal component analysis (PCA) validated the complete removal of batch clustering (S1A, B Fig). GSE183591 served as the external validation set. Additionally, a total of 35 macrophage polarization-related genes (MPRGs) were retrieved from the published literature [21]. Three M1 macrophage marker genes (TNF-α, HLA-DRα, and iNOS) and five M2 macrophage marker genes (IL-10, CCL22, ARG-1, CD206, and CD163) were retrieved from published literature [22].

2.2. Identification of differentially expressed genes (DEGs) between SCI and control groups

After batch effect correction, DEGs distinguishing SCI cases from controls within the GSE45006 and GSE45550 datasets were detected via the “limma” R package (version 3.54.0), under thresholds of adjusted P < 0.05 and |log2FC| > 0.5 [23]. Enrichment analysis for the biological functions of these DEGs (adjusted P < 0.05) was then conducted, employing the “clusterProfiler” R package (version 4.7.1) in conjunction with the “org.Rn.e.g.,db” annotation package, and leveraging resources from the Kyoto Encyclopedia of Genes and Genomes (KEGG, https://www.genome.jp/kegg/ [Accessed: March 20, 2023]) as well as Gene Ontology (GO, https://www.geneontology.org/ [Accessed: March 20, 2023]) databases [24,25].

2.3. Screening of the hub genes

DE-MPRGs were initially ascertained via the overlap between DEGs and MPRGs, computed with the aid of the “ggvenn” R package (version 0.1.9). Thereafter, selection of genes demonstrating substantial biological relevance was accomplished through application of extreme gradient boosting (XGBoost), random forest (RF), and least absolute shrinkage and selection operator (LASSO) techniques. Specifically, for the LASSO model, family = “binomial” was set to suit binary classification tasks, and type.measure = “auc” was designated as the performance evaluation metric. A regularization parameter (λ) was introduced, and lambda.min (the value yielding the minimum error) was selected as the optimal regularization parameter via 5-fold cross-validation, followed by extraction of genes with non-zero coefficients. For the RF model, optimal parameters were set as mtry = 3 and ntree = 1,000; ensemble learning across multiple decision trees reduced the variance of individual models, while built-in out-of-bag (OOB) sample validation was used instead of an independent test set to evaluate model generalization without additional sample consumption. For the XGBoost model, a reasonable learning rate (eta = 0.5), tree depth (max_depth = 5), and number of iterations (nround = 25) were configured to balance fitting ability and complexity, with gradient boosting mechanisms employed to iteratively correct errors. Hub genes were designated as those emerging from the common overlap among the three machine learning algorithms. To eliminate the potential impact of data pooling, DEGs of GSE45006 and GSE45550 were separately identified using the “limma” R package (version 3.54.0) (adjusted P < 0.05 and |log2FC| > 0.5). Subsequently, the “RobustRankAggreg” (RRA) package (version 3.54.0) was applied to integrate the ranking of DEGs across the two datasets. The aggregateRanks function was utilized to calculate the integrated score for each gene, with a lower score indicating a higher ranking. This analysis generated a cross-dataset list of significantly integrated genes, and special attention was paid to the rankings of the core genes within this integrated list.

After that, correlations between these hub genes were investigated through Spearman correlation analysis. Employing the GENEMANIA database (http://genemania.org/ [Accessed: April 27, 2023]), an interaction network linking genes for the hub genes was established. Ultimately, incorporation of the hub genes into a nomogram was achieved via the “rms” R package (version 6.2.0). Reliability of this nomogram was assessed by means of receiver operating characteristic (ROC) curves and decision curve analysis (DCA).

2.4. Gene set enrichment analysis (GSEA) of the hub genes

Training set specimens were categorized into cohorts displaying elevated and reduced expression utilizing the median values from hub genes, prompting subsequent differential expression evaluation. Genes in the entire collection received ordering according to log2FC metrics. Application of the “ClusterProfiler” R package (version 4.7.1) enabled GSEA implementation under the cutoff of adjusted P < 0.05 [26].

2.5. Ingenuity pathway analysis (IPA) of the hub genes

To explore the biological functions of the hub genes, IPA was performed based on the QIAGEN Knowledge Base (https://digitalinsights.qiagen.com/products-overview/qiagen-knowledge-base/ [Accessed: April 16, 2023]). Subsequently, we analyzed the diseases and functional annotations to which the hub genes are enriched.

2.6. Immune analysis

Gene sets pertaining to immune responses were sourced from the ImmPort repository (https://www.immport.org/ [Accessed: April 21, 2023]). Through single-sample gene set enrichment analysis (ssGSEA) executed within the “GSVA” R package (version 1.46.0), enrichment metrics for such gene sets were derived for control and SCI cohorts [27]. Variances in these enrichment metrics across the control and SCI cohorts underwent evaluation. Associations linking differentially expressed immune response gene sets to hub genes were probed via Spearman’s rank correlation technique. Moreover, marker genes indicative of human M2 and M1 macrophages were mapped to their rat orthologs employing the “homologene” R package. Scrutiny extended to the relationships connecting hub genes with these rat M1/M2 macrophage marker genes (stemming from human orthologs).

2.7. Evaluation of immune infiltration

Upon procurement of gene expression profiles, immune cell infiltration abundances were estimated employing the CIBERSORT method. Relative abundances among 22 immune cell subtypes per specimen were illustrated through stacked bar charts, alongside evaluation of infiltration variances across cohorts. Moreover, associations linking differentially infiltrated immune cell subtypes to one another, plus those connecting hub genes to such subtypes, were examined via Spearman’s rank correlation.

2.8. Creation of micro RNA (miRNAs)-mRNA network and transcription factors (TFs)-mRNA network

Orthologs corresponding to hub genes in humans were mapped through the “homologene” R package. miRNet repository (https://www.mirnet.ca/miRNet/home.xhtml [Accessed: April 29, 2023]) facilitated the forecasting of miRNAs directed toward hub genes. Concurrently, transcription factors (TFs) aimed at these genes underwent prediction leveraging the NetworkAnalyst tool (https://www.networkanalyst.ca/ [Accessed: April 30, 2023]). Interactions in TF-mRNA and miRNA-mRNA regulatory frameworks were depicted employing Cytoscape software (version 3.8.0) [28].

2.9. Drug prediction of the hub genes

Conversion to human orthologs for hub genes was executed by means of the “homologene” R package. Queries in the Drug-Gene Interaction Database (DGIdb; https://dgidb.genome.wustl.edu/ [Accessed: April 27, 2023]) relied on individual hub genes functioning as search keywords to pinpoint pharmaceuticals that engage with them.

2.10. Processing and annotation of scRNA-seq data

Analysis at the single-cell resolution scrutinized the interplay linking hub genes to macrophage polarization. Sequencing profiles derived from GSE213240 initially underwent filtration through the “Seurat” R package (version 5.0.1) [29]. In detail, quality assurance imposed three thresholds: mitochondrial gene percentage confined below 10%, detected features per cell (nFeature) bounded from 200 to 2,500, and counts per cell (nCount) capped under 6,000. Thereafter, selection of the foremost 2,000 highly variable genes occurred via the FindVariableFeatures tool, relying on the association of expression averages with dispersions; these selections persisted for ongoing evaluations. Dataset specimens subsequently experienced PCA. The JackStraw function was employed to conduct a permutation test for the null distribution, aiming to quantify the percentage of variance explained by the top 30 principal components (PCs). Prominent variance-explaining principal components (PCs) underwent selection through examination of the elbow curve diagram, whereupon cellular unsupervised grouping ensued via invocation of FindClusters and FindNeighbors functions (resolution = 0.2). Labeling and contrasting of cell identities proceeded with deployment of the “SingleR” R package (version 2.0.0) integrated alongside the CellMarker repository (http://117.50.127.228/CellMarker/ [Accessed: April 22, 2023]). Ultimately, disparities in hub gene expression across M2 and M1 macrophage populations received scrutiny (adjusted P < 0.05; Bonferroni correction).

2.11. Expression analysis of the hub genes

For additional corroboration of the robustness inherent in our results, disparities in hub gene expression across control and SCI cohorts were assessed via the Wilcoxon rank-sum test (P < 0.05) within the training cohort together with the GSE183591 collection.

2.12. Spinal cord injury rat model

Female Wistar rats in good health (Rattus norvegicus; 200 g body weight, aged 8 weeks, sourced from Janvier Labs, France) underwent random allocation into one sham-operated group and three SCI groups (3 days, 7 days, and 14 days post-injury). The initial number of animals in each SCI group was 8 rats, whereas the sham-operated group consisted of 7 rats. Compliance with the NIH Guidelines for the Care and Use of Laboratory Animals (8th edition, revised 2010, NIH) guided the investigation, wherein the fewest possible animals per cohort sufficed to yield data robust enough for statistical inference, aligning with core ethical tenets; experimental designs secured endorsement from the Anhui Medical University Animal Ethics Committee (approval LLSC20231977, Hefei, China), while every operation conformed to prevailing ethical norms and followed the ARRIVE Checklist (S1 File). Proper husbandry attended to all subjects, who occupied enclosures limited to at most three individuals apiece, maintained within specific pathogen-free (SPF) environments featuring regulated ambient temperature (22 ± 1 °C), humidity levels (50 ± 1%), alongside a 12 h light/12 h dark photoperiod. Ad libitum access prevailed for both feed and hydration.

As indicated beforehand, induction of the contusion/compression SCI paradigm relied on a customized 28 g aneurysm clip (Fehlings Laboratory, Canada). Concisely, subjects received a 1:1 blend of N₂O and O₂ alongside isoflurane (1.5–3%) for eliciting systemic anesthesia. Subsequently, posterior integument incision occurred at the T10–T8 cord segment, trailed by T9 lamina resection to unveil the neural tissue; the clip then encircled the cord and persisted for 60 s, culminating in a compression-contusion lesion [30–32]. Rats, upon emergence from anesthetic effects, exhibited trailing of hindlimbs. Laminotomy at T9, sparing neural integrity, constituted the sham cohort. Application of ocular salve averted corneal aridity, whereas a thermal mat preserved subject thermoregulation. The animals received comprehensive post-surgical care. Immediately following surgery, they were administered a subcutaneous injection of 4 ml saline. The bladder was manually emptied two to three times daily (based on signs of wet abdomen and bladder distension) until spontaneous urination was re-established. Preventive antibiotics, including 2.5% Baytril (enrofloxacin, Bayer AG, Leverkusen, Germany), meloxicam (2.0 mg/kg), and buprenorphine (0.05 mg/kg subcutaneously), were administered daily. All analgesics and antibiotics were administered daily after surgery and continued for up to seven consecutive days, or until the day of sacrifice for animals in the 3-day group. Treatment was discontinued once rats regained spontaneous urination and showed no obvious signs of pain or infection. Throughout the experiment, trained personnel monitored the animals daily for signs of pain, stress, or other discomfort. The animals’ general condition was assessed using a scoring system, and appropriate interventions were performed based on the scores to minimize suffering. If the predetermined humane endpoint criteria were met, the animals were euthanized immediately. Euthanasia was performed by placing the animals in an induction chamber and administering 5% isoflurane by inhalation until they reached a state of complete unconsciousness, as indicated by the absence of righting reflex, respiration, and response to noxious stimuli. Once unconsciousness was confirmed, subsequent experimental procedures were conducted. Animals from the experimental group were sacrificed on days 3, 7, and 14 post-SCI for spinal cord tissue collection. A total of 7 rats per group were included in the subsequent experiments (1 rat died in each SCI group during surgery or the experimental period, while all 7 rats in the sham-operated group survived). This approach ensured that the animals remained unaware during euthanasia and complied with internationally recognized guidelines, including the AVMA Guidelines for the Euthanasia of Animals (2020 Edition) and Directive 2010/63/EU of the European Parliament. Additional information is provided in the Supporting Information, including the Inclusivity in global research questionnaire (S2 File) and the PLOS ONE humane endpoints checklist (S3 File).

2.13. Reverse transcription-quantitative PCR (RT-qPCR)

T9 spinal cords were collected at 3, 7, and 14 days post-SCI or after laminectomy, immediately frozen, and stored at −80°C. Total RNA was then extracted using the NucleoSpin® RNA Isolation Kit (Macherey-Nagel GmbH & Co., Düren, Germany). Primers for each gene are listed in Table 1.

Table 1. Primers for RT-qPCR.

Gene Primers forward (5’-3’)
Myo1f Forward: TCAACCGGAACTTTGTCGGG
Reverse: AGTCCCGTTTGATGGGCTTG
Soat1 Forward: AGCCAAAGATCTGAGAGCACC
Reverse: GAACTCAAGGACCAGCCTTCC
Comt Forward: GGCCTTGAGGAGATGCCGT
Reverse: GATGCGCTGCTCCTTTGTGT
β-actin Forward: AACCTTCTTGCAGCTCCTCCG
Reverse: ATACCCACCATCACACCCTGG

Relative expression levels of specific genes/markers in RT-qPCR were assessed using the Luna® Universal RT-qPCR Master Mix system (New England Biolabs, Massachusetts, USA). RT-qPCR was performed using the StepOne Plus system (Applied Biosystems, Massachusetts, USA). Duplicate cycle thresholds (CTs) were averaged, and data were normalized to the expression of β-actin mRNA using the 2–ΔΔCt method [33].

2.14. Statistical analysis

R software (https://www.r-project.org/) enabled the implementation of all statistical computations. Disparities across cohorts received evaluation through Wilcoxon scrutiny, signifying meaningful divergence when P < 0.05. For RT-qPCR evaluations, Gaussian-form data invoked Student’s t-test application, while skewed distributions prompted Wilcoxon rank-sum deployment, with thresholds at P < 0.05 marking evidentiary weight. Multiplicity safeguards, where applicable, entailed P-value recalibration via the Benjamini-Hochberg (BH) procedure to mitigate false discovery rate (FDR).

3. Results

3.1. Acquisition and enrichment analysis of DEGs between SCI and control groups

Between SCI and control cohorts, a cohort of 1,396 DEGs surfaced, featuring 820 instances of upregulation coupled with 576 cases of downregulation (Fig 1A; S1 Table). Hierarchical clustering via heatmap illustrated the premier 20 upregulated alongside downregulated genes (Fig 1B). Herein exhibited stand the foremost 10 enriched designations from GO alongside routes from KEGG. Across 1,297 GO designations, DEGs manifested enrichment (S2 Table), partitioned into 1,094 entries for biological process (BP), 137 for cellular component (CC), and 66 for molecular function (MF). As illustrations, engagement by DEGs encompassed membrane microdomain, membrane raft, synaptic membrane, positive regulation of response to external stimulus, immune response-regulating signaling pathway, myeloid leukocyte activation, glycosaminoglycan binding, cell adhesion molecule binding, and proteoglycan binding (Fig 1C). Among the KEGG pathways, 126 were significantly enriched (S3 Table), such as osteoclast differentiation, NF-κB signaling pathway, and pertussis (Fig 1D).

Fig 1. Differentially expressed genes analysis and enrichment analysis of DEGs.

Fig 1

(A) Volcano plot of DEGs. (B) Heatmap of differentially expressed genes (Top 20 DEGs). (C) GO enrichment analysis of DEGs. (D) KEGG enrichment analysis of DEGs.

3.2. Acquisition of the hub genes

Six differentially expressed macrophage polarization-related genes (DE-MPRGs) were identified by intersecting DEGs with MPRGs: Fgd2, Soat1, Comt, Myo1f, Maf, and Sh2b2 (Fig 2A). The least absolute shrinkage and selection operator (LASSO) algorithm selected three characteristic genes: Myo1f, Soat1, and Comt (Fig 2B). The extreme gradient boosting (XGBoost) algorithm identified five characteristic genes: Fgd2, Soat1, Comt, Myo1f, and Sh2b2 (Fig 2C). The random forest (RF) algorithm identified four characteristic genes: Fgd2, Soat1, Comt, and Myo1f (Fig 2D-E). The intersection of characteristic genes from the three algorithms yielded three hub genes: Soat1, Comt, and Myo1f (Fig 2F). Meta-analysis using the RRA package revealed that three genes were stably identified in the integrated results. Specifically, Soat1 was ranked 1,336th (top 8.84%, score = 0.0936), Myo1f was ranked 1,605th (top 10.62%, score = 0.1139), and Comt was ranked 2,972nd (top 19.66%, score = 0.2258) (S4 Table). Correlation analysis revealed significant positive correlations among the hub genes (Fig 2G), with the strongest correlation between Soat1 and Myo1f (R = 0.901, P = 5.77e-18) (Fig 2H). To explore interactions among the three hub genes, a gene-gene interaction network was constructed (Fig 2I). These genes formed a complex interaction network, with the following interaction types: co-expression (39.02%), physical interactions (25.61%), predicted interactions (21.99%), pathway associations (8.15%), co-localization (2.86%), and shared protein domains (2.37%). A nomogram incorporating the three hub genes was developed to predict SCI progression (Fig 3A). The nomogram’s ROC curve yielded an area under the curve (AUC) of 0.866 (Fig 3B). The DCA curve demonstrated that the nomogram provided a higher net benefit (Fig 3C). These findings indicate that the nomogram exhibits high predictive accuracy for SCI progression.

Fig 2. Acquisition of the hub genes.

Fig 2

(A) Venn plot of DEGs and macrophage polarization related genes (MPRGs). (B) LASSO algorithm. (C) XGBoost algorithm. (D) The number of RF trees correlates with model errors. (E) Average minimum Gini coefficient diagram. (F) Venn plot of three machine learning. (G) Hub gene correlation analysis. (H) Scatter plots of the two genes with the highest positive correlation. (I) PPI protein interaction network.

Fig 3. Construction and evaluation of nomogram model.

Fig 3

(A) The nomogram containing the three hub genes. (B) ROC curve. (C) DCA curve.

3.3. Enrichment analysis of the hub genes

To further elucidate the roles of hub genes in SCI pathogenesis, GSEA was performed. The top five enriched KEGG pathways are presented. In the high-expression group, all hub genes were enriched in natural killer cell-mediated cytotoxicity, systemic lupus erythematosus, lysosome, and complement and coagulation cascades (Fig 4A-C). Additionally, both Soat1 and Myo1f were enriched in the cytokine-cytokine receptor interaction pathway in the high-expression group (Fig 4B-C).

Fig 4. GSEA analysis of the hub genes.

Fig 4

(A) GSEA analysis of Comt. (B) GSEA analysis of Soat1. (C) GSEA analysis of Myo1f.

3.4. IPA of the hub genes

A total of 582 canonical pathways were significantly enriched for DEGs between the SCI and control groups, with the top 20 enriched pathways presented (Fig 5A). The three hub genes were involved in four canonical pathways: dopamine receptor signaling, L-DOPA degradation, noradrenaline and adrenaline degradation, and dopamine degradation. Among these, the dopamine receptor signaling pathway had the highest |z-score| and is therefore illustrated in Fig 5B. In terms of disease and functional annotations, the DEGs were primarily associated with organismal injury and abnormalities (Fig 5C).

Fig 5. IPA of the hub genes.

Fig 5

(A) Top 20 classical IPA pathways (B) Interactive mapping of dopamine receptor signaling pathways. (C) Statistical analysis of disease and functional enrichment.

3.5. Immune analysis between SCI and control groups

In SCI cohorts compared to controls, eleven gene sets associated with immune responses displayed substantial differential expression, spanning tumor necrosis factor (TNF) family member receptors, T cell receptor (TCR) signaling pathway, transforming growth factor-beta (TGF-β) family member receptors, interferon receptors, natural killer cells, interleukin receptors, B cell receptor (BCR) signaling pathway, cytokine receptors, antimicrobials, chemokine receptors, and antigen processing and presentation (Fig 6A; S5 Table). Scrutiny of correlations uncovered strong positive linkages across all hub genes and every differentially expressed immune response gene set, with the peak association evident between Myo1f and the B cell receptor (BCR) signaling pathway (R = 0.925, P = 5.44e-22) (Fig 6B). The marker genes of M1 and M2 macrophages from humans were converted to their orthologous genes in rats, namely RT1-Da, Tnf, Cd163, Mrc1, Arg1, Ccl22, and Il10. The relevant analysis indicated that Mrc1 was markedly positively associated with all hub genes (Fig 6C). RT1-Da and Cd163 were markedly positively associated with Myo1f and Soat1. Additionally, Comt was negatively associated with Tnf and Ccl22.

Fig 6. Immune analysis between SCI and control groups.

Fig 6

(A) There were 11 immune response gene sets that were significantly differential between SCI and control groups. (B) Relevant analysis between hub genes and immune response. (C) The relevant analysis between hub genes and macrophage polarization markers.

3.6. Analysis of immune cell infiltration

The CIBERSORT algorithm facilitated quantification of infiltration fractions for 22 immune cell varieties within specimens, underscoring the pivotal influence of alterations in the immune milieu and associated signaling cascades on SCI advancement and recovery (Fig 7A). Elevated abundances of CD8 ⁺ T cells and resting dendritic cells marked the SCI cohort relative to controls, as our observations revealed. In opposition, the SCI ensemble manifested reduced incidences of memory CD4 ⁺ T cells, M0 macrophages, and follicular helper T cells (Tfh cells) when juxtaposed against the control ensemble (Fig 7B). Associations among immune infiltrates in these specimens underwent further interrogation (Fig 7C). Plasma cells forged a marked affirmative bond with resting natural killer (NK) cells (R = 0.63), while memory B cells evinced pronounced discord with naive B cells (R = −0.83). Associations spanning the triad of hub genes and immune infiltrates received additional examination (Fig 7D). Inverse linkages tied the three hub genes to resting memory CD4 ⁺ T cells, follicular helper T cells, M0 macrophages, and plasma cells. Affirmative ties linked every one of the three hub genes to resting dendritic cells and CD8 ⁺ T cells, mirroring the intergroup disparities noted earlier.

Fig 7. Analysis of immune cell infiltration.

Fig 7

(A) The percentage stacked column plot illustrates the relative distribution of 22 immune cell types across each sample. (B) Box plots illustrate the levels of immune cell infiltration in the SCI and control groups. (C) The correlation heatmap illustrates the relationships between different immune cell compositions. (D) Heatmap of hub genes correlation with immune cells.

3.7. The TF-mRNA-miRNA networks

Elucidation of the mechanistic underpinnings dictating hub gene operations in SCI necessitated assembly of regulatory architectures encompassing miRNA-mRNA and TF-mRNA interactions. The miRNA-mRNA construct, encompassing 273 miRNAs alongside 3 mRNAs (specifically, the set of three hub genes), emerged (Fig 8A). Illustrative regulatory pairings spanned MYO1F-hsa-miR-27b-3p, SOAT1-hsa-miR-485-5p, COMT-hsa-miR-637, and similar associations. Complementing this, the TF-mRNA framework integrated 30 TFs with the 3 mRNAs (i.e., the three hub genes) (Fig 8B). For instance, the TF TEAD1 could regulate SOAT1 and COMT. Three TFs (TFAP2C, NFKB1, and CREB1) were common TFs regulating both COMT and MYO1F.

Fig 8. The networks of hub genes.

Fig 8

(A) The miRNA-mRNA network of hub genes. (B) The TF-mRNA network of hub genes. (C) The hub gene-drug interaction network.

3.8. Drug prediction

The hub gene-drug interaction network was constructed using DGIdb. The results revealed that a total of 37 small-molecule drugs were predicted by the database (Fig 8C). Five small-molecule drugs were associated with SOAT1: nifedipine, dexamethasone, testosterone, atorvastatin, and lovastatin. For COMT, 32 small-molecule drugs were predicted, including fluvoxamine, tolcapone, and entacapone. However, no small-molecule drugs were predicted for MYO1F as the target gene.

3.9. Differential expression of hub genes between different macrophage polarization states

In GSE213240, a total of 66,093 cells and 19,404 genes met the inclusion criteria (S2A Fig, B). Subsequent analysis identified 2,000 highly variable genes with the greatest variance, such as Igfbp5 (Fig 9A). Among these, the top 30 principal components (PCs) contributed the most to the variation (Fig 9B-9C). Clustering based on the top 30 PCs resulted in 17 cell clusters (Fig 9D). These clusters were classified into nine cell types, including T cells, B cells, M2 macrophages, M1 macrophages, oligodendrocytes, NK cells, endothelial cells, granulocytes, and monocytes. In SCI samples, granulocytes represented the largest proportion, followed by M1 macrophages, indicating an inflammatory microenvironment in SCI (Fig 9E). Notably, Soat1, Comt, and Myo1f showed significant differential expression between M1 and M2 macrophages, all being highly expressed in M1 macrophages (adjusted P < 0.0001, log2FC > 1.50) (Fig 9F). These findings further confirm the association of these hub genes with the inflammatory microenvironment of SCI.

Fig 9. Significant differences exist in the expression of hub genes between M1 and M2 macrophages.

Fig 9

(A) Visualization of highly variable genes. Red dots indicate highly variable genes, while black dots represent non-highly variable genes. (B) Jackstraw plot for PCA. The horizontal axis shows empirical values calculated by the Jackstraw function, the vertical axis displays computed theoretical values, and the legend on the right indicates the P-value for each principal component. (C) Number of available dimensions in the fragment plot. The horizontal axis represents the number of PCs, while the vertical axis shows the standard deviation. (D) UMAP plot of cell clusters. The x-axis represents the first principal component axis after UMAP dimensionality reduction, while the y-axis represents the second principal component axis. Points of different colors denote distinct cell clusters. (E) UMAP plot of annotation results for 9 cell types across all samples. (F) Violin plots showing the expression levels of Soat1, Comt, and Myo1f in M1 and M2 macrophages.The overlaid box plot (white) illustrates the median and interquartile range, while the scatter plot displays the expression values of individual cells. Between-group comparisons were performed using the Wilcoxon rank-sum test with Bonferroni correction for multiple testing.

3.10. The expression levels of the hub genes

The expression of hub genes between the SCI and control groups was further analyzed in the training set and the GSE183591 dataset using the Wilcoxon test (Fig 10A, 10B). The results demonstrated a significant difference in the expression of all hub genes between the SCI and control groups in the training set, with higher expression levels observed in the SCI group (Fig 10A). In the GSE183591 dataset, the expression trends of all hub genes were consistent with those in the training set (Fig 10B). These findings suggest that all hub genes exhibit strong diagnostic potential for SCI.

Fig 10. The expression levels of the hub genes.

Fig 10

(A) The expression of all hub genes of SCI group was markedly higher in the training set. (B) In GSE183591, the expression of all hub genes of SCI group was markedly higher.

3.11. Validation of hub genes by RT-qPCR

RT-qPCR was performed on rat spinal cord tissue samples collected at 3, 7, and 14 days post-SCI to validate the reliability of the hub genes identified through database analysis. Consistent with the findings from the GEO databases, the expression levels of Soat1, Comt, and Myo1f were significantly elevated in the SCI group compared to the control group at all time points (Fig. 11, S6 Table). These results corroborated the data mining outcomes, further reinforcing the reliability of our findings.

Fig 11. Verification of differentially expressed hub gene mRNAs.

Fig 11

Relative mRNA expression levels of the Comt, Myo1f, and Soat1 genes were assessed in both injured spinal cord and sham spinal cord samples by RT-qPCR at different time points. Data are expressed as the mean ± SD (n = 7). *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test).

4. Discussion

Activation of the innate immune response initiates post-SCI inflammatory cascades, with early stages chiefly defined by microglia and macrophage polarization [13,34]. Functional implications of DEGs underwent initial scrutiny in our work through GO and KEGG pathway enrichment evaluations. Substantial GO term accumulations for DEGs involved positive regulation of response to external stimuli, myeloid leukocyte activation, and immune response-regulating signaling pathway. KEGG pathway evaluations further disclosed DEG associations with pertussis pathway, NF-kappa B signaling pathway, and osteoclast differentiation. These results suggested that significant changes occur in the inflammatory microenvironment following SCI, and the associated MPRGs may play a crucial role in this process. LASSO, RF, and XGBoost algorithms were used to screen for hub genes; as a result, three hub genes (Soat1, Comt, and Myo1f) were identified. These results suggest that significant changes occur in the inflammatory microenvironment following SCI, and the associated MPRGs may play a critical role in this process. Sterol O-acyltransferase 1 (SOAT1/ACAT1) is a key enzyme in lipid metabolism. Recent studies have shown that inhibiting SOAT1 promotes M2 macrophage polarization, reduces inflammatory responses, and supports functional recovery following SCI [35]. This finding suggests that modulating Soat1 activity may represent a promising therapeutic approach to enhance tissue repair after SCI. Myo1f (Myosin IF) encodes a non-conventional myosin that hydrolyzes ATP to generate mechanical force and supports actin-dependent cellular motility. Emerging evidence indicates that Myo1f is essential for neutrophil locomotion within three-dimensional matrices during acute inflammatory responses and is upregulated following SCI [36]. Furthermore, previous studies have demonstrated that genetic ablation of Myo1f attenuates microglial activation, dampens inflammatory signaling, and reduces overall immune reactivity [37]. In peripheral T-cell lymphoma, the Vav1–Myo1f fusion drives CD4 ⁺ T-cell transformation and disrupts normal T-cell differentiation, accompanied by increased tumor-associated macrophages (TAMs). In the corresponding mouse model, the spleen contains a distinct macrophage subset co-expressing M2 and TAM markers, suggesting a close mechanistic link between Myo1f and macrophage polarization [38]. Myo1f and Soat1 regulate cell adhesion/migration and mediate cholesterol esterification metabolism, respectively. Both have been implicated in regulating macrophage polarization and directional chemotactic motility [39,40]. Catechol-O-methyltransferase (Comt) is an enzyme that facilitates O-methylation and effectively inactivates catechol-containing molecules. It has been reported to attenuate the anti-inflammatory effects of luteolin by promoting methylation [41]. Comt plays a central role in pain modulation, inflammatory regulation, and cognitive processes [42–44]. At the single-cell level, M1 macrophages represented the second-largest cell population, reflecting the pronounced inflammatory microenvironment at the injury site. The three hub genes exhibited distinct expression patterns between M1 and M2 polarization states, with consistent upregulation in M2 macrophages, indicating a close association with macrophage phenotypes and the local inflammatory milieu. These findings provide single-cell-level evidence linking the hub genes to macrophage functional states and the surrounding microenvironment, offering cellular insights into their potential role in immune modulation following central nervous system injury.

GSEA results indicated that all hub genes were involved in natural killer cell-mediated cytotoxicity, systemic lupus erythematosus, lysosome function, and complement and coagulation cascades. Moreover, immune-related gene set enrichment analysis revealed that Soat1, Comt, and Myo1f were significantly positively correlated with all 11 immune response gene sets that were differentially expressed between the SCI and control groups. Notably, NK cells play a crucial role in defending against bacterial and viral infections through their effector functions. They are also believed to significantly contribute to the immune dysfunction that arises following SCI. These findings suggest that the hub genes may have a pivotal role in SCI through various pathways, particularly those related to immune responses.

It is well established that miRNAs and TFs are essential regulators in the growth, development, and regeneration of the central nervous system (CNS). Given their regulatory roles in the pathophysiology of various diseases, we constructed miRNA-mRNA and TF-mRNA regulatory networks for the identified hub genes. Identifying the miRNAs and TFs within these networks may potentially shed light on the gene regulatory mechanisms governing the polarization of macrophages and microglia during SCI. For instance, it has been shown that inhibition of miR-27b-3p reduces microglial apoptosis after SCI and attenuates the production of inflammatory factors by microglia [45]. Another study demonstrated that miR-211-5p alleviates neuron apoptosis and inflammation induced by SCI by directly targeting activating transcription factor 6 (ATF6) and regulating endoplasmic reticulum stress in a rat mode [46]. The present analyses highlighted CREB1 and NFKB1 as key targets in the constructed TF-mRNA regulatory network, which are closely associated with COMT and MYO1F. A previous study demonstrated that pentraxin 3 (PTX3) promotes M2 macrophage polarization via the CREB1/CEBPB axis, thereby contributing to stromal cell-mediated immune regulation [47]. Another study revealed that NFKB1 is the most highly expressed TF in macrophages—key cellular drivers of inflammation and immunity [47,48]. The aforementioned findings may serve as important therapeutic targets for SCI and facilitate a deeper understanding of the mechanisms underlying the hub genes’ roles in SCI.

We used the DGIdb to identify 37 small-molecule drugs predicted to interact with these hub genes. These agents will provide crucial guidance for further translational research and the development of viable therapeutic strategies for SCI. Interestingly, several of these drugs have already demonstrated efficacy in treating SCI in animal models and are associated with degenerative processes linked to SCI. For instance, nifedipine may help prevent adverse blood pressure responses after SCI. Evidence indicates that anti-inflammatory actions arise from its blockade of nitric oxide (NO) synthesis via inducible nitric oxide synthase (iNOS) within macrophages, coupled with interleukin-1β curtailment [49]. Functioning as a manufactured glucocorticoid, dexamethasone (Dex) curbs macrophage elaboration of pro-inflammatory agents while curtailing apoptosis-associated cellular demise, in turn promoting expedited functional amelioration following SCI [50,51]. Another finding indicates that testosterone promotes macrophage polarization toward the M2 phenotype and suppresses M1 polarization through Gαi- and Akt-dependent signaling pathways [52]. Additionally, evidence supports that adjuvant testosterone, when used as part of a multimodal approach, facilitates neuromuscular recovery following SCI [52,53]. Atorvastatin and lovastatin have been reported to suppress the production of inflammatory mediators by macrophages and promote neurological function recovery in models of traumatic brain injury (TBI) and SCI [54–57]. In TBI models, fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), has been shown to exert neuroprotective and anti-inflammatory effects [58]. However, further research is required to ascertain whether these drugs exert similar effects in SCI, as well as to investigate their underlying pharmacological mechanisms.

Despite providing novel bioinformatic insights into macrophage polarization in SCI, several limitations must be addressed before translating these findings into clinical applications. First, the reliance on bulk RNA sequencing limits the resolution to distinguish cell-subtype-specific gene expression, particularly among macrophage polarization states, thus restricting the precise functional interpretation of hub genes. While scRNA-seq analyses using tools such as Seurat enable cell clustering and differential expression analysis, they remain insufficient for accurately defining continuous polarization phenotypes or capturing low-abundance, polarization-specific transcripts, which may affect the interpretation of the macrophage polarization spectrum. Second, although hub genes such as SOAT1, COMT, and MYO1F were enriched in immune-related pathways, their direct roles in regulating macrophage phenotype transitions (e.g., M1/M2 balance), underlying mechanisms, and therapeutic potential remain largely unexplored, with current evidence limited to preliminary in vivo experiments. Third, the relatively small sample size may limit statistical power and introduce potential selection bias.

Future work should address these gaps in three areas: (1) increasing the sample size across diverse injury severities, disease stages, and demographic backgrounds to reduce bias and enhance generalizability; (2) employing macrophage-specific genetic manipulations, such as conditional knockouts or overexpression, to validate the direct effects on macrophage polarization, cytokine secretion, and functional recovery after SCI; and (3) applying spatial and co-localization techniques, such as double immunofluorescence, to verify hub gene expression in macrophages within tissue contexts, further validating these findings in clinical samples. Given the high disability and economic burden associated with SCI, validating these targets could provide molecular entry points for precise therapeutic interventions and establish potential biomarkers for dynamic monitoring and individualized treatment strategies in SCI and related neurological disorders.

5. Conclusions

In summary, macrophage polarization plays a critical role in the progression and functional outcomes of SCI. In this study, we comprehensively analyzed the expression profiles of macrophage polarization–related genes in SCI and, through systematic bioinformatics approaches, identified three hub genes (Soat1, Comt, and Myo1f) that are closely associated with this process. These findings deepen our understanding of the pathophysiological mechanisms underlying macrophage polarization–mediated neuroinflammation and tissue injury/repair following SCI, and provide novel therapeutic targets and a theoretical basis for clinical intervention. Based on our results, targeted modulation of Soat1, Comt, and Myo1f may represent a promising strategy to optimize macrophage polarization, suppress detrimental neuroinflammation, and ultimately maximize neuroprotection and functional recovery after SCI. Future studies should focus on gene-specific intervention strategies to facilitate the translation of these findings into effective therapeutic approaches.

Supporting information

S1 Table. The results of differential expression analysis between control and SCI samples in the training set.

(XLSX)

pone.0347599.s001.xlsx (157KB, xlsx)
S2 Table. 1,297 GO items of DEGs.

(XLSX)

pone.0347599.s002.xlsx (188.9KB, xlsx)
S3 Table. 126 enriched pathways of DEGs.

(XLSX)

pone.0347599.s003.xlsx (25.1KB, xlsx)
S4 Table. The integrated results of the two datasets analyzed by RRA package.

(XLSX)

pone.0347599.s004.xlsx (472.2KB, xlsx)
S5 Table. The enrichment results of gene set enrichment analysis (GSEA) for the hub genes.

(XLSX)

pone.0347599.s005.xlsx (21.7KB, xlsx)
S6 Table. RT-qPCR data for selected hub genes.

(XLSX)

pone.0347599.s006.xlsx (10.6KB, xlsx)
S1 Fig. Batch effects were removed after merging the GSE45550 and GSE45006 datasets.

(A) Before batch effect correction. (B) After batch effect correction, showing excellent batch integration.

(TIF)

pone.0347599.s007.TIF (335KB, TIF)
S2 Fig. The quality control of single-cell RNA sequencing (scRNA-seq) data.

(A, B) Distribution plots of nFeature_RNA, nCount_RNA, and percent.mt before (A) and after quality control (B).

(TIF)

pone.0347599.s008.TIF (915.2KB, TIF)
S1 File. ARRIVE Checklist.

(PDF)

pone.0347599.s009.pdf (185.6KB, pdf)
S2 File. Inclusivity in global research questionnaire.

(DOCX)

pone.0347599.s010.docx (65.1KB, docx)
S3 File. PLOS ONE humane endpoints checklist.

(DOCX)

pone.0347599.s011.docx (42.8KB, docx)

Data Availability

All gene expression data used in this study were obtained from the Gene Expression Omnibus (GEO) database, which is hosted by the National Center for Biotechnology Information (NCBI; https://www.ncbi.nlm.nih.gov/geo/). The unique accession numbers for the relevant datasets are as follows: GSE45550, GSE45006, GSE183591, and GSE213240. All datasets are freely accessible without additional authorization via the search function on the GEO database official website (by entering the corresponding accession number). No new original datasets were generated in this study. Additional processed data and analysis outputs related to this work are provided in the Supporting Information.

Funding Statement

This work was supported by the General Programs of Natural Science Research of Anhui Provincial Education Department (Grant No. ZR2022B001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Chi G, Lu J, He T, Wang Y, Zhou X, Zhang Y, et al. High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury. Sci Rep. 2024;14(1):22344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Silva NA, Sousa N, Reis RL, Salgado AJ. From basics to clinical: a comprehensive review on spinal cord injury. Prog Neurobiol. 2014;114:25–57. doi: 10.1016/j.pneurobio.2013.11.002 [DOI] [PubMed] [Google Scholar]
  • 3.Chen Y, Tang Y, Vogel L, DeVivo M. Causes of spinal cord injury. Topics in spinal cord injury rehabilitation. 2013;19(1):1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002;359(9304):417–25. doi: 10.1016/S0140-6736(02)07603-1 [DOI] [PubMed] [Google Scholar]
  • 5.Furlan JC, Sakakibara BM, Miller WC, Krassioukov AV. Global incidence and prevalence of traumatic spinal cord injury. Can J Neurol Sci. 2013;40(4):456–64. doi: 10.1017/s0317167100014530 [DOI] [PubMed] [Google Scholar]
  • 6.Jazayeri SB, Beygi S, Shokraneh F, Hagen EM, Rahimi-Movaghar V. Incidence of traumatic spinal cord injury worldwide: a systematic review. Eur Spine J. 2015;24(5):905–18. doi: 10.1007/s00586-014-3424-6 [DOI] [PubMed] [Google Scholar]
  • 7.Singh A, Tetreault L, Kalsi-Ryan S, Nouri A, Fehlings MG. Global prevalence and incidence of traumatic spinal cord injury. Clin Epidemiol. 2014;6:309–31. doi: 10.2147/CLEP.S68889 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Zhang Y, Zhou Y, Chen S, Hu Y, Zhu Z, Wang Y, et al. Macrophage migration inhibitory factor facilitates prostaglandin E2 production of astrocytes to tune inflammatory milieu following spinal cord injury. J Neuroinflammation. 2019;16(1):85. doi: 10.1186/s12974-019-1468-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ji H, Zhang Y, Chen C, Li H, He B, Yang T, et al. D-dopachrome tautomerase activates COX2/PGE2 pathway of astrocytes to mediate inflammation following spinal cord injury. J Neuroinflammation. 2021;18(1):130. doi: 10.1186/s12974-021-02186-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zha X, Zheng G, Skutella T, Kiening K, Unterberg A, Younsi A. Microglia: a promising therapeutic target in spinal cord injury. Neural Regen Res. 2025;20(2):454–63. doi: 10.4103/NRR.NRR-D-23-02044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Daemen S, Gainullina A, Kalugotla G, He L, Chan MM, Beals JW, et al. Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. Cell Rep. 2021;34(2):108626. doi: 10.1016/j.celrep.2020.108626 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Sterner RC, Sterner RM. Immune response following traumatic spinal cord injury: Pathophysiology and therapies. Front Immunol. 2023;13:1084101. doi: 10.3389/fimmu.2022.1084101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Fu S-P, Chen S-Y, Pang Q-M, Zhang M, Wu X-C, Wan X, et al. Advances in the research of the role of macrophage/microglia polarization-mediated inflammatory response in spinal cord injury. Front Immunol. 2022;13:1014013. doi: 10.3389/fimmu.2022.1014013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Shan K, Feng N, Cui J, Wang S, Qu H, Fu G, et al. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J Cell Mol Med. 2020;24(14):8045–56. doi: 10.1111/jcmm.15436 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kisucká A, Bimbová K, Bačová M, Gálik J, Lukáčová N. Activation of Neuroprotective Microglia and Astrocytes at the Lesion Site and in the Adjacent Segments Is Crucial for Spontaneous Locomotor Recovery after Spinal Cord Injury. Cells. 2021;10(8):1943. doi: 10.3390/cells10081943 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207. doi: 10.1038/s41392-023-01452-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vitaliti A, Reggio A, Palma A. Macrophages and autophagy: partners in crime. FEBS J. 2025;292(12):2957–72. doi: 10.1111/febs.17305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Dussold C, Zilinger K, Turunen J, Heimberger AB, Miska J. Modulation of macrophage metabolism as an emerging immunotherapy strategy for cancer. J Clin Invest. 2024;134(2):e175445. doi: 10.1172/JCI175445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Baligand C, Chen Y-W, Ye F, Pandey SN, Lai S-H, Liu M, et al. Transcriptional Pathways Associated with Skeletal Muscle Changes after Spinal Cord Injury and Treadmill Locomotor Training. Biomed Res Int. 2015;2015:387090. doi: 10.1155/2015/387090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Martínez-Rojas B, Giraldo E, Grillo-Risco R, Hidalgo MR, López-Mocholi E, Alastrue-Agudo A, et al. NPC transplantation rescues sci-driven cAMP/EPAC2 alterations, leading to neuroprotection and microglial modulation. Cell Mol Life Sci. 2022;79(8):455. doi: 10.1007/s00018-022-04494-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zhao Y, Li M, Yang Y, Wu T, Huang Q, Wu Q, et al. Identification of Macrophage Polarization-Related Genes as Biomarkers of Chronic Obstructive Pulmonary Disease Based on Bioinformatics Analyses. Biomed Res Int. 2021;2021:9921012. doi: 10.1155/2021/9921012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yang L-F, Zhang Z-B, Wang L. S100A9 promotes tumor-associated macrophage for M2 macrophage polarization to drive human liver cancer progression: An in vitro study. Kaohsiung J Med Sci. 2023;39(4):345–53. doi: 10.1002/kjm2.12651 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi: 10.1093/nar/gkv007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Zha X. Identification of novel biomarkers and immune characteristics of spinal cord injury based on comprehensive bioinformatic analysis: A retrospective observational study. NeuroMarkers. 2025;2(2):100077. doi: 10.1016/j.neumar.2025.100077 [DOI] [Google Scholar]
  • 26.Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. The innovation. 2021;2(3). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. doi: 10.1186/1471-2105-14-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Killcoyne S, Carter GW, Smith J, Boyle J. Cytoscape: a community-based framework for network modeling. Methods Mol Biol. 2009;563:219–39. doi: 10.1007/978-1-60761-175-2_12 [DOI] [PubMed] [Google Scholar]
  • 29.Zhang Q, Yu B, Zhang Y, Tian Y, Yang S, Chen Y, et al. Combination of single-cell and bulk RNA seq reveals the immune infiltration landscape and targeted therapeutic drugs in spinal cord injury. Front Immunol. 2023;14:1068359. doi: 10.3389/fimmu.2023.1068359 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zheng G, Harms A-K, Tail M, Zhang H, Nimmo A, Skutella T, et al. Effects of a neurokinin-1 receptor antagonist in the acute phase after thoracic spinal cord injury in a rat model. Front Mol Neurosci. 2023;16:1128545. doi: 10.3389/fnmol.2023.1128545 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Li Z, Yu S, Liu Y, Hu X, Li Y, Xiao Z, et al. SU16f inhibits fibrotic scar formation and facilitates axon regeneration and locomotor function recovery after spinal cord injury by blocking the PDGFRβ pathway. J Neuroinflammation. 2022;19(1):95. doi: 10.1186/s12974-022-02449-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Younsi A, Zheng G, Scherer M, Riemann L, Zhang H, Tail M, et al. Three Growth Factors Induce Proliferation and Differentiation of Neural Precursor Cells In Vitro and Support Cell-Transplantation after Spinal Cord Injury In Vivo. Stem Cells Int. 2020;2020:5674921. doi: 10.1155/2020/5674921 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. doi: 10.1006/meth.2001.1262 [DOI] [PubMed] [Google Scholar]
  • 34.Marschallinger J, Iram T, Zardeneta M, Lee SE, Lehallier B, Haney MS, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci. 2020;23(2):194–208. doi: 10.1038/s41593-019-0566-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Peng P, Wang H, Pang Z, Zhang H, Hu S, Ma X, et al. Macrophage polarization-related gene SOAT1 is involved in inflammatory response and functional recovery after spinal cord injury. Mol Cell Biochem. 2025;480(7):4197–212. doi: 10.1007/s11010-025-05246-7 [DOI] [PubMed] [Google Scholar]
  • 36.Salvermoser M, Pick R, Weckbach LT, Zehrer A, Löhr P, Drechsler M, et al. Myosin 1f is specifically required for neutrophil migration in 3D environments during acute inflammation. Blood. 2018;131(17):1887–98. doi: 10.1182/blood-2017-10-811851 [DOI] [PubMed] [Google Scholar]
  • 37.Wang Y, Zhao X, Gao M, Wan X, Guo Y, Qu Y, et al. Myosin 1f-mediated activation of microglia contributes to the photoreceptor degeneration in a mouse model of retinal detachment. Cell Death Dis. 2021;12(10):926. doi: 10.1038/s41419-021-03983-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cortes JR, Filip I, Albero R, Patiño-Galindo JA, Quinn SA, Lin W-HW, et al. Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma. Cell Rep. 2022;39(3). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhao C, Yang Q, Tang R, Li W, Wang J, Yang F, et al. DNA methyltransferase 1 deficiency improves macrophage motility and wound healing by ameliorating cholesterol accumulation. NPJ Regen Med. 2023;8(1):29. doi: 10.1038/s41536-023-00306-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Piedra-Quintero ZL, Serrano C, Villegas-Sepúlveda N, Maravillas-Montero JL, Romero-Ramírez S, Shibayama M, et al. Myosin 1F Regulates M1-Polarization by Stimulating Intercellular Adhesion in Macrophages. Front Immunol. 2019;9:3118. doi: 10.3389/fimmu.2018.03118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ye L, Xin Y, Wu Z-Y, Sun H-J, Huang D-J, Sun Z-Q. A Newly Synthesized Flavone from Luteolin Escapes from COMT-Catalyzed Methylation and Inhibits Lipopolysaccharide-Induced Inflammation in RAW264.7 Macrophages via JNK, p38 and NF-κB Signaling Pathways. J Microbiol Biotechnol. 2022;32(1):15–26. doi: 10.4014/jmb.2104.04027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Polli A, Hendrix J, Ickmans K, Bakusic J, Ghosh M, Monteyne D, et al. Genetic and epigenetic regulation of Catechol-O-methyltransferase in relation to inflammation in chronic fatigue syndrome and Fibromyalgia. J Transl Med. 2022;20(1):487. doi: 10.1186/s12967-022-03662-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kim S, Zhang X, O’Buckley SC, Cooter M, Park JJ, Nackley AG. Acupuncture Resolves Persistent Pain and Neuroinflammation in a Mouse Model of Chronic Overlapping Pain Conditions. J Pain. 2018;19(12):1384.e1-1384.e14. doi: 10.1016/j.jpain.2018.05.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Saloner R, Marquine MJ, Sundermann EE, Hong S, McCutchan JA, Ellis RJ, et al. COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV. J Acquir Immune Defic Syndr. 2019;81(5):e148–57. doi: 10.1097/QAI.0000000000002083 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Li L, Qi C, Liu Y, Shen Y, Zhao X, Qin H, et al. MicroRNA miR-27b-3p regulate microglial inflammation response and cell apoptosis by inhibiting A20 (TNF-α-induced protein 3). Bioengineered. 2021;12(2):9902–13. doi: 10.1080/21655979.2021.1969195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Zhang H, Piao M, Guo M, Meng L, Yu H. MicroRNA-211-5p attenuates spinal cord injury via targeting of activating transcription factor 6. Tissue Cell. 2021;68:101459. doi: 10.1016/j.tice.2020.101459 [DOI] [PubMed] [Google Scholar]
  • 47.Chen F-W, Wu Y-L, Cheng C-C, Hsiao Y-W, Chi J-Y, Hung L-Y, et al. Inactivation of pentraxin 3 suppresses M2-like macrophage activity and immunosuppression in colon cancer. J Biomed Sci. 2024;31(1):10. doi: 10.1186/s12929-023-00991-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Best KT, Lee FK, Knapp E, Awad HA, Loiselle AE. Deletion of NFKB1 enhances canonical NF-κB signaling and increases macrophage and myofibroblast content during tendon healing. Sci Rep. 2019;9(1):10926. doi: 10.1038/s41598-019-47461-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Choe S-H, Choi E-Y, Hyeon J-Y, Keum BR, Choi IS, Kim S-J. Effect of nifedipine, a calcium channel blocker, on the generation of nitric oxide and interleukin-1β by murine macrophages activated by lipopolysaccharide from Prevotella intermedia. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(1):59–71. doi: 10.1007/s00210-020-01958-3 [DOI] [PubMed] [Google Scholar]
  • 50.Zurita M, Vaquero J, Oya S, Morales C. Effects of dexamethasone on apoptosis-related cell death after spinal cord injury. J Neurosurg. 2002;96(1 Suppl):83–9. doi: 10.3171/spi.2002.96.1.0083 [DOI] [PubMed] [Google Scholar]
  • 51.O’Neil JD, Bolimowska OO, Clayton SA, Tang T, Daley KK, Lara-Reyna S, et al. Dexamethasone impairs the expression of antimicrobial mediators in lipopolysaccharide-activated primary macrophages by inhibiting both expression and function of interferon β. Front Immunol. 2023;14:1190261. doi: 10.3389/fimmu.2023.1190261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Ren X, Fu X, Zhang X, Chen S, Huang S, Yao L, et al. Testosterone regulates 3T3-L1 pre-adipocyte differentiation and epididymal fat accumulation in mice through modulating macrophage polarization. Biochem Pharmacol. 2017;140:73–88. doi: 10.1016/j.bcp.2017.05.022 [DOI] [PubMed] [Google Scholar]
  • 53.Otzel DM, Lee J, Ye F, Borst SE, Yarrow JF. Activity-Based Physical Rehabilitation with Adjuvant Testosterone to Promote Neuromuscular Recovery after Spinal Cord Injury. Int J Mol Sci. 2018;19(6):1701. doi: 10.3390/ijms19061701 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Gao S, Zhang Z-M, Shen Z-L, Gao K, Chang L, Guo Y, et al. Atorvastatin activates autophagy and promotes neurological function recovery after spinal cord injury. Neural Regen Res. 2016;11(6):977–82. doi: 10.4103/1673-5374.184498 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Yang N, Cheng W, Hu H, Xue M, Li X, Wang Y, et al. Atorvastatin attenuates sympathetic hyperinnervation together with the augmentation of M2 macrophages in rats postmyocardial infarction. Cardiovasc Ther. 2016;34(4):234–44. doi: 10.1111/1755-5922.12193 [DOI] [PubMed] [Google Scholar]
  • 56.Xu X, Gao W, Cheng S, Yin D, Li F, Wu Y, et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J Neuroinflammation. 2017;14(1):167. doi: 10.1186/s12974-017-0934-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Mirzaie J, Nasiry D, Ayna Ö, Raoofi A, Delbari A, Rustamzadeh A, et al. Neuroprotective effects of lovastatin against traumatic spinal cord injury in rats. J Chem Neuroanat. 2022;125:102148. doi: 10.1016/j.jchemneu.2022.102148 [DOI] [PubMed] [Google Scholar]
  • 58.Shi M, Mi L, Li F, Li Y, Zhou Y, Chen F, et al. Fluvoxamine Confers Neuroprotection via Inhibiting Infiltration of Peripheral Leukocytes and M1 Polarization of Microglia/Macrophages in a Mouse Model of Traumatic Brain Injury. J Neurotrauma. 2022;39(17–18):1240–61. doi: 10.1089/neu.2021.0355 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Sawar Khan

10 Oct 2025

-->PONE-D-25-22705-->-->Screening macrophage polarization genes in spinal cord injury as therapeutic targets-->-->PLOS ONE

Dear Dr. Cao,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 25 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols..

We look forward to receiving your revised manuscript.

Kind regards,

Sawar Khan, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

3. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

https://www.sciencedirect.com/science/article/pii/S2950588725000424?via%3Dihub

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

4. Thank you for stating the following financial disclosure:

“This work was supported by General Programs of Natural Science Research of Anhui Provincial Education Department (Grant No. ZR2022B001).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: No

Reviewer #2: No

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: No

Reviewer #2: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: Introductory comment

--------------------------

In the manuscript titled “Screening macrophage polarization genes in spinal cord injury as therapeutic targets”, Xiaowei et al. attempt to explore an understudied area of macrophage polarization in spinal cord injury (SCI). To achieve this, the authors adopted a fairly comprehensive bioinformatics analysis, ranging from screening differential gene expression analysis (MPRGs) to miRNA/TF regulatory network construction. Furthermore, the authors explored external validation of the three final DEGs (via qPCR testing). Overall, the study is sound, timely, and worth considering. However, the manuscript can further be fine-tuned by addressing a couple of sections.

Core strengths

-----------------

Standard bioinformatics pipeline: Robust feature-selection techniques (random forest, LASSO, and gradient boosting) and enrichment methods were used to screen the differentially expressed genes. Performing batch correction via the sva package is particularly commendable.

Immunoinfiltration and function pathway analysis: The authors used ssGSEA to highlight functional pathway enrichment of the screened genes, as well as using CIBERSORT to underscore the role of the identified genes in the immune cell infiltration within the tumor microenvironment.

Regulatory and gene-drug interaction network: The authors further performed TF-miRNA and drug-gene interaction analysis to illustrate or reveal translational relevance.

External validation: Though not a strong point, performing in vivo qPCR validation in rat models adds further insights (with respect to predictions).

Weaknesses

--------------

Pre-processing: Though it is mentioned that batch correction was performed (i.e., using the sva package), the manuscript is quite silent on key data pre-processing methods. This aspect should be addressed. The datasets used are described in moderate detail (e.g., platform types like GPL1355 and GPL4135). Additionally, the sample sizes are small, which implies the authors ought to describe how they dealt with sample-size bias.

Lack of in-depth discussion of the SCI hub genes: A detailed contextual discussion of the screened genes in SCI would further strengthen the manuscript. While gene ontology (GO/KEGG) was performed, discussion of the MPGRs with respect to past studies has not been thoroughly discussed.

Language clarity: The language can further be improved. There are some weird spelling errors (aftereffects → after-effects). Italicize the ‘genus’ and ‘species’ names (e.g., Rattus norvegicus → Rattus norvegicus). Using the word ‘gained’ in the expression “Firstly, the DE-MPRGs were gained through taking the intersection” does not quite appear standard.

Limitations of the study: Clearly, this study has a couple of limitations not mentioned in the manuscript. For example, single-cell RNA analysis (Seurat package) was performed. Therefore, the authors could dedicate a paragraph to pointing out areas lacking in the current study, as well as further direction (if any).

Reviewer #2: The manuscript is comprehensive and methodologically sound, providing a solid foundation for the study’s conclusions. The study offers a comprehensive bioinformatics analysis aimed at identifying macrophage polarization-related genes involved in spinal cord injury (SCI). The multi-step approach —encompassing DEG screening, GO/KEGG enrichment analyses, machine learning algorithms (LASSO, XGBoost, RF), gene-gene interaction networks, and drug prediction — is well-designed and leads to valuable insights. Addressing the following points with additional details and clarifications would improve transparency, and reproducibility.

- It would enhance reproducibility if the authors provide more information on the specific parameters or methods used for batch effect correction. Additionally, including a visualization (e.g., PCA or MDS plots) before and after batch effect removal would help readers assess the effectiveness of this step.

- I recommend using GridSearchCV to improve the performance of each machine learning algorithms.

- The application of the “limma” package with clear thresholds (P < 0.05, |log2FC| > 0.5) is appropriate for identifying DEGs. Functional enrichment via GO and KEGG pathways using “clusterProfiler” and “org.Rn.eg.db” packages is well described. Nevertheless, the authors should clarify whether multiple testing corrections (e.g., FDR adjustment) were applied and specify the exact adjusted P-value thresholds for enrichment analyses.

- Employing three machine learning algorithms (LASSO, Random Forest, and XGBoost) for biomarker selection is a strong approach. However, detailed information about the tuning parameters, cross-validation strategy, and feature selection criteria for each algorithm is missing and should be provided to enhance reproducibility. Also, a brief description of how the final biomarker set was validated (e.g., internal validation metrics or external validation) would strengthen this section.

- Given the study's focus on macrophage polarization, incorporating or referencing single-cell transcriptomics data would improve resolution and specificity. The authors are encouraged to discuss this limitation more explicitly in the discussion section

- To firmly establish the involvement of the identified hub genes in macrophages, the use of co-localization techniques (e.g., double immunofluorescence or in situ hybridization) is recommended. This would strengthen the claim that these genes are functionally active in macrophage populations post-SCI.

- Although the study briefly discusses the biological roles of *Soat1*, *Comt*, and *Myo1f*, a more in-depth analysis of their functions in neuroinflammation and SCI — supported by relevant literature — would be valuable.

- Literatures are taken from old papers where enhanced version of clustering techniques are available. So, add some more recent literatures and compare the work with proposed one.

- The section about the future study should be mentioned in the last paragraph of the Conclusion section.

- Please expand on how the findings can be practically integrated into clinical or public health strategies?

- The quality of the figures should be improved.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #1: Yes: Abubakari Sumaila SalpawuniAbubakari Sumaila Salpawuni

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-25-22705-reporting.pdf

pone.0347599.s012.pdf (400.9KB, pdf)
PLoS One. 2026 May 4;21(5):e0347599. doi: 10.1371/journal.pone.0347599.r002

Author response to Decision Letter 1


4 Dec 2025

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Re: We sincerely thank the PLOS ONE editorial team for reviewing our manuscript and providing valuable comments. We have carefully considered all suggestions and have thoroughly revised the manuscript to comply with the formatting requirements and editorial guidance provided.

2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

Re: We have carefully reviewed PLOS’ policy on inclusivity in global research and completed the corresponding questionnaire as required, and appropriately cited it in the Materials and methods section (Line 280-282). The completed questionnaire has been included as a Supporting Information file with the revised manuscript, and we believe this addition further enhances the transparency of our study.

3. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

https://www.sciencedirect.com/science/article/pii/S2950588725000424?via%3Dihub

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

Re: We sincerely thank the editor for the careful review of our manuscript and for providing valuable comments regarding textual presentation. We have taken the issue of textual overlap very seriously and conducted a thorough check and revision of the entire manuscript. During the revision process, we carefully cross-checked all cited references and substantively rewrote and restructured sections of the Introduction, Discussion, and other parts where overlaps were identified, ensuring originality in language expression. While some bioinformatic analysis methods, such as hub gene selection via machine learning, are standard in the field, the novelty of this study lies in the integration of transcriptomic data with single-cell RNA-seq, allowing higher-resolution analysis of macrophage subpopulation dynamics, and in the experimental validation of selected hub genes in vivo—work that has not been systematically reported in the existing literature. We have conducted a similarity/plagiarism check on the manuscript and confirm that the revised version fully addresses any issues of textual overlap, ensuring original language and proper citation throughout. We appreciate your guidance, which has helped us more clearly highlight the unique contributions of this study, and we respectfully submit the manuscript for further consideration.

4. Thank you for stating the following financial disclosure:

“This work was supported by General Programs of Natural Science Research of Anhui Provincial Education Department (Grant No. ZR2022B001).”

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Re: Thank you very much for reviewing our manuscript and providing valuable comments. In response to the request for an updated financial disclosure statement, we have complied accordingly. The funder (General Programs of Natural Science Research of Anhui Provincial Education Department, Grant No. ZR2022B001) had no role in any aspect of this study. Accordingly, we have included the following revised statement in our cover letter:

"This work was supported by the General Programs of Natural Science Research of Anhui Provincial Education Department (Grant No. ZR2022B001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

We confirm that this statement is accurate. We would appreciate the journal’s assistance in updating the corresponding information in the online submission system. Thank you again for your guidance.

5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Re: We sincerely thank the editor for reviewing our manuscript and for providing valuable comments. We have taken note of the suggestion regarding reference citations. We carefully reviewed and evaluated the publications mentioned by the reviewers and have cited them judiciously in the revised manuscript where appropriate.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Re: We sincerely thank you for your recognition of the technical rigor, data reliability, and validity of the conclusions in our study. We are pleased that the scientific quality of our manuscript has been acknowledged. We remain committed to rigorous research and have carefully revised and improved the manuscript based on the other suggestions provided.

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Re: We sincerely thank you for acknowledging the rigor and appropriateness of the statistical analyses in our study. We remain committed to conducting our research with objective and rigorous statistical standards.

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

Re: Thank you for reviewing our manuscript and providing valuable comments. We fully recognize the shortcomings regarding data availability and take this issue seriously. To comply with PLOS data policies, we have submitted the raw data underlying all statistical figures/charts as Supporting Information, and updated the Data Availability Statement to include repository names, accession numbers, and direct access links, ensuring that all data are publicly accessible without restriction. Additionally, key datasets supporting critical results are provided alongside the manuscript to enhance reproducibility and transparency. We are committed to fully implementing these changes in the revised manuscript, ensuring that all data are completely accessible, traceable, and in compliance with journal requirements, and we sincerely appreciate your suggestions for improving the scientific rigor of our work.

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Re: We sincerely thank the reviewer for the valuable comments, particularly regarding the clarity and precision of the language. In response to the issues highlighted by Reviewer #1, we have thoroughly polished the manuscript, correcting grammatical and spelling errors, inappropriate expressions, and potentially ambiguous sentences, while also optimizing the logic and structure and reorganizing some lengthy or obscure paragraphs to ensure clear, accurate, and easily understandable presentation. The revised manuscript reflects all these improvements, and we greatly appreciate the meticulous work of the reviewers and editors, which has been instrumental in enhancing the quality of our study.

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Introductory comment

--------------------------

In the manuscript titled “Screening macrophage polarization genes in spinal cord injury as therapeutic targets”, Xiaowei et al. attempt to explore an understudied area of macrophage polarization in spinal cord injury (SCI). To achieve this, the authors adopted a fairly comprehensive bioinformatics analysis, ranging from screening differential gene expression analysis (MPRGs) to miRNA/TF regulatory network construction. Furthermore, the authors explored external validation of the three final DEGs (via qPCR testing). Overall, the study is sound, timely, and worth considering. However, the manuscript can further be fine-tuned by addressing a couple of sections.

Core strengths

-----------------

Standard bioinformatics pipeline: Robust feature-selection techniques (random forest, LASSO, and gradient boosting) and enrichment methods were used to screen the differentially expressed genes. Performing batch correction via the sva package is particularly commendable.

Immunoinfiltration and function pathway analysis: The authors used ssGSEA to highlight functional pathway enrichment of the screened genes, as well as using CIBERSORT to underscore the role of the identified genes in the immune cell infiltration within the tumor microenvironment.

Regulatory and gene-drug interaction network: The authors further performed TF-miRNA and drug-gene interaction analysis to illustrate or reveal translational relevance.

External validation: Though not a strong point, performing in vivo qPCR validation in rat models adds further insights (with respect to predictions).

Weaknesses

--------------

Pre-processing: Though it is mentioned that batch correction was performed (i.e., using the sva package), the manuscript is quite silent on key data pre-processing methods. This aspect should be addressed. The datasets used are described in moderate detail (e.g., platform types like GPL1355 and GPL4135). Additionally, the sample sizes are small, which implies the authors ought to describe how they dealt with sample-size bias.

Re: We sincerely thank you for your recognition of the value of our study and for your insightful comments regarding data preprocessing and sample size, which have been crucial in enhancing the rigor and clarity of our manuscript. In response, we have expanded the “Materials and Methods” section to provide detailed information on the quality control steps performed prior to batch correction and to explain the statistical rationale for the chosen preprocessing procedures, ensuring data reliability and comparability. We have also addressed concerns regarding the limited sample size by emphasizing in the Methods the use of robust statistical approaches and cross-validation techniques to reduce the risk of overfitting, and by acknowledging in the Discussion this limitation while highlighting the need for validation in larger independent cohorts. These revisions aim to present the study’s limitations more comprehensively and demonstrate our careful consideration of these issues. We greatly appreciate your insightful comments, which have significantly improved the quality of our manuscript, and we hope that these modifications fully address your concerns.

Lack of in-depth discussion of the SCI hub genes: A detailed contextual discussion of the screened genes in SCI would further strengthen the manuscript. While gene ontology (GO/KEGG) was performed, discussion of the MPGRs with respect to past studies has not been thoroughly discussed.

Re: We sincerely thank you for this insightful and constructive comment. We fully agree that a thorough comparison and interpretation of the selected hub genes within the context of existing literature is crucial for enhancing the academic value of the manuscript. Following your suggestion, we have revised and expanded the Discussion section. Rather than merely describing the results of GO/KEGG enrichment analyses, we have examined each of the final hub genes in the context of current literature, deepening the discussion of their known functions in SCI or other neurological disorders and the consistency of our findings with previous studies. We have also integrated insights from the literature and single-cell analyses to elucidate the relationships between these genes and macrophage polarization, highlighting the novelty of our study in identifying potential key targets. We believe that these additions and elaborations now allow the Discussion section to more fully interpret the potential significance of our findings. We greatly appreciate your guidance, which has significantly strengthened the depth of our manuscript.

Language clarity: The language can further be improved. There are some weird spelling errors (aftereffects → after-effects). Italicize the ‘genus’ and ‘species’ names (e.g., Rattus norvegicus → Rattus norvegicus). Using the word ‘gained’ in the expression “Firstly, the DE-MPRGs were gained through taking the intersection” does not quite appear standard.

Limitations of the study: Clearly, this study has a couple of limitations not mentioned in the manuscript. For example, single-cell RNA analysis (Seurat package) was performed. Therefore, the authors could dedicate a paragraph to pointing out areas lacking in the current study, as well as further direction (if any).

Re: We sincerely thank you for your specific and valuable suggestions regarding language details and the limitations of our study. We have carefully revised the manuscript based on each of your comments.

1. Language clarity: We have thoroughly proofread and polished the entire manuscript. Specific revisions include correcting spelling errors, ensuring proper formatting of all biological genus and species names, and replacing non-standard expressions with more precise academic language.

2. Study limitations: We fully agree with your points and have added a dedicated section on limitations and future directions at the end of the Discussion. This section addresses potential biases associated with retrospective analyses based on public databases, the inherent limitations of bulk RNA-seq data in distinguishing cell types, the current shortcomings of scRNA-seq analyses in precisely defining continuous phenotypes, and the preliminary nature of the

Attachment

Submitted filename: Response to Reviewers.docx

pone.0347599.s015.docx (33.2KB, docx)

Decision Letter 1

Sawar Khan

18 Feb 2026

-->PONE-D-25-22705R1-->-->Screening macrophage polarization genes in spinal cord injury as therapeutic targets-->-->PLOS One

Dear Dr. Cao,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 04 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols..

We look forward to receiving your revised manuscript.

Kind regards,

Sawar Khan, Ph.D

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #1: All comments have been addressed

Reviewer #3: (No Response)

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

Reviewer #3: Yes

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #3: Yes

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #3: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #3: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: This revised manuscript has been significantly improved. In the original version, my concerns largely revolved around issues of preprocessing (e.g., small sample size), lack of detailed discussion of the SCI hub genes screened, language clarity, and failure to acknowledge the limitations of the present study. All these issues have largely been addressed now.

Minor suggestion:

Since the GSE45006 and GSE45550 datasets were used to screen the DEGs (using the `limma` package) for the downstream analyses, the findings in the study can further be strengthened using the DExMA package or the `Robust Rank Aggregation` (RRA) package for meta-analysis of the GSE45006 and GSE45550 datasets. Using these two packages, can the approach used in DOI: https://doi.org/10.3390/diagnostics15141770 be applicable to your study? How are your findings strengthened?

Since links to web tools are susceptible to changes in the future, the authors are strongly advised to include the date accessed for the web links in their study. As an example, the authors state

“Queries in the Drug-Gene Interaction Database (DGIdb; https://dgidb.genome.wustl.edu/) relied on individual hub genes …”

It should be

“Queries in the Drug-Gene Interaction Database (DGIdb; https://dgidb.genome.wustl.edu/ [Accessed: June 23, 2025]) relied on individual hub genes …” Notice that in the second case, we indicate the web tool was accessed on June 23, 2025.

Reviewer #3: I reviewed the revised manuscript which respond to the comments of previous reviewers who mostly focused on the data gathering and bioinformatic analysis. In summary this manuscript tried to identify the genes involved in macrophages polarization after SCI by recruiting data bases and doing bioinformatic analyses. They find three genes in their research and then bring them to the bench in order to evaluate their mRNA expression. I have some comments to more polish the animal study.

- Duration of receiving pain killers and antibiotic should be stated.

- clear group description and number of animals in each group required.

- use one format of genes names. International abbreviation usage is required such as Comt change to COMT, Myo1f to MYO1F and so on

- fig-9- To me the level of expression of desired gene in M1 and M2 macrophages does not have significant difference.

- for functionality of a gene usually we check the end product of a gene which is protein level. I didn't see any western blot or ELISA study in this work.

- I need to see a clear suggestion for future studies in conclusion section showing us based on this study who can we reach to maximum protection in SCI by manipulating these genes.

- Taken together, this study brings new hypothesis which needs to be evaluated by further animal and clinical trial studies.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #1: No

Reviewer #3: Yes: Mahmoudreza HadjighassemMahmoudreza Hadjighassem

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

Attachment

Submitted filename: Report-manuscript-PONE-D-25-22705R1.pdf

pone.0347599.s014.pdf (281.4KB, pdf)
PLoS One. 2026 May 4;21(5):e0347599. doi: 10.1371/journal.pone.0347599.r004

Author response to Decision Letter 2


24 Mar 2026

Point-by-point response to the editor and reviewer comments

Dear Editor and Reviewers,

Thank you very much for your continued evaluation of our manuscript and for your insightful comments and valuable suggestions. We sincerely appreciate your time and effort throughout the review process.

We have carefully revised the manuscript again in response to all the comments raised in this round of review. A detailed, point-by-point response to each comment is provided below. All changes have been clearly indicated in the revised manu-script. We have made every effort to address all remaining concerns and further im-prove the clarity, rigor, and completeness of the study.

We hope that the revised manuscript now meets the requirements for publication in PLOS ONE. Please do not hesitate to contact us if further clarification is needed.

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Re: N/A。

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the re-buttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Re: Thank you for your suggestion. We have carefully reviewed and standardized the reference list to ensure its accuracy and completeness. We identified that Reference 35 in the previous version, Retracted Article: Strontium-doped gelatin scaffolds promote M2 macrophage switch and angiogenesis through modulating the polariza-tion of neutrophils, had been retracted.

In accordance with the journal’s requirements, we removed this reference and re-placed it with a relevant and valid article of similar scientific significance: Macro-phage polarization-related gene SOAT1 is involved in inflammatory response and functional recovery after spinal cord injury. The manuscript has been updated ac-cordingly.

________________________________________

Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This revised manuscript has been significantly improved. In the origi-nal version, my concerns largely revolved around issues of preprocessing (e.g., small sample size), lack of detailed discussion of the SCI hub genes screened, language clarity, and failure to acknowledge the limitations of the present study. All these is-sues have largely been addressed now.

Re:Thank you very much for your careful evaluation and valuable comments. We are pleased that the current revision has largely addressed the concerns you previ-ously raised, including data preprocessing, in-depth discussion of SCI-related hub genes, language clarity, and the acknowledgment of study limitations. We sincerely appreciate your professional guidance.

Minor suggestion:

Since the GSE45006 and GSE45550 datasets were used to screen the DEGs (using the `limma` package) for the downstream analyses, the findings in the study can fur-ther be strengthened using the DExMA package or the `Robust Rank Aggregation` (RRA) package for meta-analysis of the GSE45006 and GSE45550 datasets. Using these two packages, can the approach used in DOI: https://doi.org/10.3390/diagnostics15141770 be applicable to your study? How are your findings strengthened?

Re:We sincerely thank you for your valuable suggestion. In response, we have per-formed additional analyses, and the results have been incorporated into the revised manuscript (without track changes) (lines 151–157, 350-353). The corresponding results have also been provided in the Supplementary Materials for your review.

Specifically, after identifying the hub genes, we applied the same significance thresholds to screen differentially expressed genes (DEGs) from the GSE45006 and GSE45550 datasets. We then used the RobustRankAggreg (RRA) package to inte-grate the ranked DEG lists from the two datasets. The aggregateRanks function was employed to calculate integrated scores and generate a cross-dataset ranked gene list. Based on this, we evaluated the ranking positions of the three hub genes (Soat1, Myo1f, and Comt) within the integrated list.

The rankings and corresponding RRA scores of the three hub genes are as follows: Soat1 ranked 1,336 (top 8.84%, Score = 0.0936), Myo1f ranked 1,605 (top 10.62%, Score = 0.1139), and Comt ranked 2,972 (top 19.66%, Score = 0.2258). Although these genes were not among the top 20 or top 100 in the integrated list, they were consistently retained in the RRA results and ranked within the upper-middle range across all genes.

Since links to web tools are susceptible to changes in the future, the authors are strongly advised to include the date accessed for the web links in their study. As an example, the authors state“Queries in the Drug-Gene Interaction Database (DGIdb; https://dgidb.genome.wustl.edu/) relied on individual hub genes …”

It should be

“Queries in the Drug-Gene Interaction Database (DGIdb; https://dgidb.genome.wustl.edu/ [Accessed: June 23, 2025]) relied on individual hub genes …” Notice that in the second case, we indicate the web tool was accessed on June 23, 2025.

Re:Thank you very much for your valuable suggestion. In response, we have added the specific access dates for all web-based tools used in this study and standardized the citation format of online resources. These revisions have been incorporated into the manuscript, improving the rigor and clarity of our presentation.

Reviewer #3: I reviewed the revised manuscript which respond to the comments of previous reviewers who mostly focused on the data gathering and bioinformatic analysis. In summary this manuscript tried to identify the genes involved in macro-phages polarization after SCI by recruiting data bases and doing bioinformatic anal-yses. They find three genes in their research and then bring them to the bench in or-der to evaluate their mRNA expression. I have some comments to more polish the animal study.

-Duration of receiving pain killers and antibiotic should be stated.

-clear group description and number of animals in each group required.

Re:We sincerely thank you for your valuable suggestions, which have greatly con-tributed to improving the methodological clarity and rigor of the animal experiments in this study. In response to your comments regarding the need for a clear descrip-tion of experimental groups and the number of animals in each group, as well as the duration of analgesic and antibiotic administration, we have carefully revised and supplemented the Methods section as follows:

At the beginning of the animal model description, we have clearly defined the exper-imental groups as one sham-operated group and three SCI groups corresponding to 3, 7, and 14 days post-injury. We have explicitly stated the initial number of animals in each group (8 rats per SCI group and 7 rats in the sham group), as well as the final number of animals included in the analyses (7 rats per group across all four groups).

In addition, in the postoperative care section, all analgesics and antibiotics were ad-ministered daily after surgery and continued for up to seven consecutive days, or un-til the day of sacrifice for animals in the 3-day group. Treatment was discontinued once rats regained spontaneous urination and showed no obvious signs of pain or in-fection.

All relevant revisions have been clearly indicated in the revised manuscript (see Section 2.12, “Spinal cord injury rat model”).

- use one format of genes names. International abbreviation usage is required such as Comt change to COMT, Myo1f to MYO1F and so on.

Re:Thank you very much for your valuable suggestion regarding gene nomencla-ture. According to the official rat gene naming conventions (RGD), rat gene symbols are formatted with only the first letter capitalized (e.g., Comt, Myo1f, Soat1). To maintain standard academic conventions for rat model studies, we have consistently applied the standardized rat gene nomenclature throughout the manuscript, ensuring uniformity and correctness.

The inconsistencies in gene name capitalization that you noted mainly occurred in the enrichment analysis, IPA analysis, and molecular regulation-related sections. These discrepancies arose because the study involved homologous gene conversion between rat and human, where some genes were presented according to their human gene annotation formats, leading to differences in capitalization.

In summary, we sincerely thank you for your valuable comment. Your careful review and professional suggestions have greatly contributed to improving the quality of our manuscript, and we have carefully revised the text accordingly.

- fig-9- To me the level of expression of desired gene in M1 and M2 macrophages does not have significant difference.

Re:Thank you very much for your careful evaluation of the results presented in Figure 9. We have supplemented the analysis with detailed statistical testing. Specif-ically, the Wilcoxon rank-sum test was applied to assess differential expression of the three genes. The raw P values for Soat1, Comt, and Myo1f were 1.09 × 10⁻22, 1.95 × 10⁻⁹⁹, and 1.61 × 10⁻181, respectively. After Bonferroni correction for multi-ple comparisons, all adjusted P values remained far below 0.0001, indicating ex-tremely strong statistical significance.

The corresponding log2 fold changes were 1.722, 1.555, and 3.920, respectively, all exceeding a two-fold change, thus demonstrating clear biological relevance. In terms of cellular expression patterns, all three genes showed high expression in M1 mac-rophages and were nearly absent in M2 macrophages, with no overlap in the inter-quartile ranges between the two groups, indicating a distinct distribution difference.

We have also optimized the figure by annotating adjusted P values and log2FC, and by adding scatter plots to display single-cell expression distributions, making the results more intuitive.

Taken together, these results demonstrate that the three hub genes exhibit highly sig-nificant and biologically meaningful differences in expression between M1 and M2 macrophages. We sincerely appreciate your valuable suggestion.

- for functionality of a gene usually we check the end product of a gene which is pro-tein level. I didn't see any western blot or ELISA study in this work.

Re:Thank you very much for your valuable suggestion. We fully agree that valida-tion at the protein level is important for elucidating gene function. In this study, based on a rat spinal cord injury model, we systematically assessed the expression changes of key genes at three consecutive time points (3, 7, and 14 days post-injury) using RT-qPCR. The results demonstrated highly consistent, robust, and time-dependent expression patterns across these time points, providing strong transcrip-tional evidence supporting the reliability and dynamic regulation of these genes dur-ing the pathological progression of spinal cord injury.

We acknowledge that protein-level validation, such as Western blot or ELISA, was not performed in the present study. In future work, we will build upon these findings to further investigate the expression and functional roles of these genes at the pro-tein level. We sincerely appreciate your professional and insightful comments.

- I need to see a clear suggestion for future studies in conclusion section showing us based on this study who can we reach to maximum protection in SCI by manipulat-ing these genes.

Re: Thank you very much for your important suggestion. In response, we have re-vised the Conclusion section to include future research directions based on our find-ings. Specifically, we propose that modulation of the key genes identified in this study may further elucidate their neuroprotective roles in spinal cord injury, thereby providing potential therapeutic targets and experimental evidence for maximizing neuroprotection after SCI.

In addition, future studies may incorporate strategies such as gene overexpression, knockdown, or pharmacological targeting to investigate the synergistic regulatory effects of these genes, with the aim of optimizing approaches for clinical translation and functional recovery.

We sincerely appreciate your valuable comments, which have greatly improved the completeness and significance of our manuscript.

- Taken together, this study brings new hypothesis which needs to be evaluated by further animal and clinical trial studies.

Re:Thank you very much for your valuable comments. We fully agree with your perspective. In the present study, the expression of the hub genes was only prelimi-narily validated using RT-qPCR, and the hypotheses generated still require further verification through more in-depth experimental and clinical studies.

In the revised manuscript, we have highlighted these limitations in the Discussion section. Future work will focus on mechanistic validation in animal models as well as clinical translation, in order to systematically evaluate the reliability and applica-bility of this hypothesis. We sincerely appreciate your insightful suggestions, which have provided important direction for our future research and have greatly improved the rigor and completeness of this manuscript.

Attachment

Submitted filename: Response_to_Reviewers_auresp_2.docx

pone.0347599.s016.docx (26.3KB, docx)

Decision Letter 2

Sawar Khan

6 Apr 2026

Screening macrophage polarization genes in spinal cord injury as therapeutic targets

PONE-D-25-22705R2

Dear Dr. Cao,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support..

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Sawar Khan, Ph.D

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #1: All comments have been addressed

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: (No Response)

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: (No Response)

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: (No Response)

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: (No Response)

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: (No Response)

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #1: No

**********

Acceptance letter

Sawar Khan

PONE-D-25-22705R2

PLOS One

Dear Dr. Cao,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sawar Khan

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. The results of differential expression analysis between control and SCI samples in the training set.

    (XLSX)

    pone.0347599.s001.xlsx (157KB, xlsx)
    S2 Table. 1,297 GO items of DEGs.

    (XLSX)

    pone.0347599.s002.xlsx (188.9KB, xlsx)
    S3 Table. 126 enriched pathways of DEGs.

    (XLSX)

    pone.0347599.s003.xlsx (25.1KB, xlsx)
    S4 Table. The integrated results of the two datasets analyzed by RRA package.

    (XLSX)

    pone.0347599.s004.xlsx (472.2KB, xlsx)
    S5 Table. The enrichment results of gene set enrichment analysis (GSEA) for the hub genes.

    (XLSX)

    pone.0347599.s005.xlsx (21.7KB, xlsx)
    S6 Table. RT-qPCR data for selected hub genes.

    (XLSX)

    pone.0347599.s006.xlsx (10.6KB, xlsx)
    S1 Fig. Batch effects were removed after merging the GSE45550 and GSE45006 datasets.

    (A) Before batch effect correction. (B) After batch effect correction, showing excellent batch integration.

    (TIF)

    pone.0347599.s007.TIF (335KB, TIF)
    S2 Fig. The quality control of single-cell RNA sequencing (scRNA-seq) data.

    (A, B) Distribution plots of nFeature_RNA, nCount_RNA, and percent.mt before (A) and after quality control (B).

    (TIF)

    pone.0347599.s008.TIF (915.2KB, TIF)
    S1 File. ARRIVE Checklist.

    (PDF)

    pone.0347599.s009.pdf (185.6KB, pdf)
    S2 File. Inclusivity in global research questionnaire.

    (DOCX)

    pone.0347599.s010.docx (65.1KB, docx)
    S3 File. PLOS ONE humane endpoints checklist.

    (DOCX)

    pone.0347599.s011.docx (42.8KB, docx)
    Attachment

    Submitted filename: PONE-D-25-22705-reporting.pdf

    pone.0347599.s012.pdf (400.9KB, pdf)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0347599.s015.docx (33.2KB, docx)
    Attachment

    Submitted filename: Report-manuscript-PONE-D-25-22705R1.pdf

    pone.0347599.s014.pdf (281.4KB, pdf)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_2.docx

    pone.0347599.s016.docx (26.3KB, docx)

    Data Availability Statement

    All gene expression data used in this study were obtained from the Gene Expression Omnibus (GEO) database, which is hosted by the National Center for Biotechnology Information (NCBI; https://www.ncbi.nlm.nih.gov/geo/). The unique accession numbers for the relevant datasets are as follows: GSE45550, GSE45006, GSE183591, and GSE213240. All datasets are freely accessible without additional authorization via the search function on the GEO database official website (by entering the corresponding accession number). No new original datasets were generated in this study. Additional processed data and analysis outputs related to this work are provided in the Supporting Information.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES